Sikang Ruiqi

Sikang Ruiqi is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative small molecule drugs for oncology and autoimmune diseases. The company utilizes a proprietary structure-based drug design (SBDD) platform to develop highly selective and potent kinase inhibitors. Its lead candidate, SK-002, is a selective CDK2 inhibitor currently in Phase 1 clinical trials, aimed at treating patients with advanced solid tumors, particularly those who have developed resistance to CDK4/6 inhibitors. Founded in 2021 by industry veterans, the company has successfully raised significant capital from prominent investors such as Qiming Venture Partners and IDG Capital. Sikang Ruiqi focuses on addressing significant unmet medical needs through differentiated therapeutic mechanisms.